Monopar Therapeutics Inc. (MNPR) 10-Year Financial Performance & Capital Metrics

MNPR • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.Show more

Revenue $0
EBITDA -$16M -83.0%
Net Income -$16M -85.5%
EPS (Diluted) -1.36 -134.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -51.42% +52.0%
ROIC -321.43% +94.3%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 20.9% through buybacks

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Expensive at 14.4x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-200.27%

EPS CAGR

10Y-

5Y-

3Y-

TTM-350%

ROCE

10Y Avg-75.7%

5Y Avg-67.43%

3Y Avg-79.5%

Latest-53.32%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	688.56K	1.19M	16.6M	3.4M	4.32M	6.51M	9.13M	10.54M	8.83M	16.16M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	587.08K	912.47K	1.17M	1.63M	2.36M	2.44M	2.63M	2.95M	3.23M	3.16M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	101.49K	280.36K	935.32K	1.77M	1.97M	4.07M	6.49M	7.59M	5.6M	13.01M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	14.5M	0	0	0	0	0	0	0
Operating Income+	-689K	-1.19M	-16.6M	-3.4M	-4.32M	-6.51M	-9.13M	-10.54M	-8.83M	-16.16M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.73%	-12.92%	0.8%	-0.27%	-0.51%	-0.4%	-0.15%	0.16%	-0.83%
EBITDA+	-438	0	-14.5M	-72K	-4.22M	0	-9.13M	-10.54M	-8.83M	-16.16M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	1%	-	1%	-57.68%	1%	-	-0.15%	0.16%	-0.83%
D&A (Non-Cash Add-back)	688.56K	1.19M	2.1M	3.33M	0	6.51M	0	0	0	0
EBIT	-687K	-1.18M	-16.55M	-3.33M	-4.22M	-6.51M	-9.13M	-10.54M	-8.83M	-16.16M
Net Interest Income+	0	0	0	0	98.89K	81.9K	24.02K	21.24K	429.04K	404.02K
Interest Income	1.25K	7.23K	48.26K	103.22K	98.89K	81.9K	24.02K	21.24K	429.04K	404.02K
Interest Expense	0	7.23K	48.26K	103.22K	0	0	0	0	0	0
Other Income/Expense	1.25K	7.23K	48.26K	31.15K	98.89K	204.3K	24.02K	21.24K	429.04K	575.3K
Pretax Income+	-687K	-1.18M	-16.55M	-3.3M	-4.22M	-6.3M	-9.1M	-10.52M	-8.4M	-15.59M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	800	0	-71.61K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.98%	1%	1%	1%	1%	1%	1%
Net Income+	-687K	-1.19M	-16.55M	-3.23M	-4.22M	-6.3M	-9.1M	-10.52M	-8.4M	-15.59M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.73%	-12.96%	0.81%	-0.31%	-0.49%	-0.44%	-0.16%	0.2%	-0.86%
Net Income (Continuing)	-687K	-1.19M	-16.55M	-3.23M	-4.22M	-6.3M	-9.1M	-10.52M	-8.4M	-15.59M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.08	-0.12	-1.59	-0.31	-0.40	-0.58	-0.73	-0.83	-0.58	-1.36
EPS Growth %	-	-0.43%	-12.25%	0.81%	-0.29%	-0.45%	-0.26%	-0.14%	0.3%	-1.34%
EPS (Basic)	-0.08	-0.12	-1.59	-0.31	-0.40	-0.58	-0.73	-0.83	-0.58	-1.36
Diluted Shares Outstanding	8.16M	9.86M	10.42M	10.42M	10.59M	10.96M	12.47M	12.72M	14.51M	11.48M
Basic Shares Outstanding	8.16M	9.85M	10.42M	10.42M	10.59M	10.96M	12.47M	12.72M	14.51M	11.44M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.03M	2.1M	9.13M	7.32M	13.23M	16.8M	20.52M	13.17M	7.33M	60.29M
Cash & Short-Term Investments	2.01M	2.07M	8.98M	6.89M	13.21M	16.74M	20.3M	13.12M	7.27M	60.21M
Cash Only	2.01M	2.07M	8.98M	6.89M	13.21M	16.74M	20.3M	8.19M	7.27M	45.82M
Short-Term Investments	0	0	0	0	0	0	0	4.93M	0	14.4M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	15.71K	62.69K	217.75K	45.98K	66.43K	78.87K
Total Non-Current Assets+	800K	800.39K	800.03K	410.67K	122.38K	68.86K	0	61.23K	12.65K	0
Property, Plant & Equipment	0	0	0	0	0	0	0	61.23K	12.65K	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	730.65M	0	0	0	0	0	0	0
Long-Term Investments	800K	800.39K	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	-729.85M	410.67K	122.38K	68.86K	0	0	0	0
Total Assets+	2.83M	2.9M	9.93M	7.32M	13.35M	16.87M	20.52M	13.23M	7.35M	60.29M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	0.02%	2.43%	-0.26%	0.82%	0.26%	0.22%	-0.36%	-0.44%	7.21%
Total Current Liabilities+	73.84K	64.51K	311.87K	399.55K	724.16K	1.18M	1.58M	3.13M	1.76M	5.25M
Accounts Payable	73.84K	64.51K	311.87K	399.55K	724.16K	1.18M	1.58M	3.13M	1.76M	2.25M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	0	0	0
Current Ratio	27.46x	32.48x	29.28x	18.32x	18.27x	14.28x	12.98x	4.21x	4.17x	11.47x
Quick Ratio	27.46x	32.48x	29.28x	18.32x	18.27x	14.28x	12.98x	4.21x	4.17x	11.47x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	0	8.41K	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	8.41K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	73.84K	64.51K	311.87K	399.55K	724.16K	1.18M	1.58M	3.14M	1.76M	5.25M
Total Debt+	0	0	0	0	0	0	0	8.41K	0	0
Net Debt	-2.01M	-2.07M	-8.98M	-6.89M	-13.21M	-16.74M	-20.3M	-8.18M	-7.27M	-45.82M
Debt / Equity	-	-	-	-	-	-	-	0.00x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-164.94x	-344.07x	-32.97x	-	-	-	-	-	-
Total Equity+	2.75M	2.83M	9.62M	6.92M	12.63M	15.69M	18.94M	10.09M	5.59M	55.04M
Equity Growth %	-	0.03%	2.4%	-0.28%	0.83%	0.24%	0.21%	-0.47%	-0.45%	8.85%
Book Value per Share	0.34	0.29	0.92	0.66	1.19	1.43	1.52	0.79	0.39	4.79
Total Shareholders' Equity	2.75M	2.83M	9.62M	6.92M	12.63M	15.69M	18.94M	10.09M	5.59M	55.04M
Common Stock	0	0	9.29K	9.29K	10.59K	11.45K	12.6K	12.95K	14.9K	6.1K
Retained Earnings	-687.31K	-1.87M	-18.43M	-21.66M	-25.88M	-32.19M	-41.29M	-51.8M	-60.21M	-75.79M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-2.4K	-10.97K	-7.87K	-3.16K	8.94K	-14.13K	35.99K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-636.33K	-1.19M	-2.63M	-2.89M	-3.02M	-4.66M	-7.32M	-7.23M	-7.86M	-6.4M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.88%	-1.2%	-0.1%	-0.05%	-0.54%	-0.57%	0.01%	-0.09%	0.19%
Net Income	-687.31K	-1.19M	-16.55M	-3.23M	-4.22M	-6.3M	-9.1M	-10.52M	-8.4M	-15.59M
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	0	0	305.2K	529.33K	1.01M	1.32M	1.47M	1.64M	1.9M	1.14M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-73.84K	9.33K	13.5M	441.65K	0	-122.4K	0	0	0	4.55M
Working Capital Changes	50.98K	-9.04K	120.58K	-188.16K	196.02K	443.81K	317.77K	1.65M	-1.35M	3.49M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	73.84K	-9.33K	247.36K	87.68K	243.53K	447.6K	403.97K	1.48M	-1.33M	506.79K
Cash from Investing+	0	0	0	0	0	0	0	-4.92M	4.93M	-14.34M
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	3.44M	1.26M	9.54M	-206.27K	9.35M	8.18M	10.88M	32.87K	2.03M	59.29M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	3.44M	0	4.83M	-206.27K	-874.81K	-115.57K	-45.77K	-76.46K	-46.97K	-104.14K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-636.33K	-1.19M	-2.63M	-2.89M	-3.02M	-4.66M	-7.32M	-7.23M	-7.86M	-6.4M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.88%	-1.2%	-0.1%	-0.05%	-0.54%	-0.57%	0.01%	-0.09%	0.19%
FCF per Share	-0.08	-0.12	-0.25	-0.28	-0.29	-0.43	-0.59	-0.57	-0.54	-0.56
FCF Conversion (FCF/Net Income)	0.93x	1.01x	0.16x	0.89x	0.71x	0.74x	0.80x	0.69x	0.94x	0.41x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-24.94%	-42.45%	-265.93%	-39.04%	-43.23%	-44.52%	-52.57%	-72.44%	-107.19%	-51.42%
Return on Invested Capital (ROIC)	-	-118.69%	-1784.05%	-769.75%	-	-	-	-2878.57%	-5671.91%	-321.43%
Debt / Equity	-	-	-	-	-	-	-	0.00x	-	-
Interest Coverage	-	-164.94x	-344.07x	-32.97x	-	-	-	-	-	-
FCF Conversion	0.93x	1.01x	0.16x	0.89x	0.71x	0.74x	0.80x	0.69x	0.94x	0.41x

Frequently Asked Questions

Growth & Financials

Monopar Therapeutics Inc. (MNPR) grew revenue by 0.0% over the past year. Growth has been modest.

Monopar Therapeutics Inc. (MNPR) reported a net loss of $19.4M for fiscal year 2024.

Dividend & Returns

Monopar Therapeutics Inc. (MNPR) has a return on equity (ROE) of -51.4%. Negative ROE indicates the company is unprofitable.

Monopar Therapeutics Inc. (MNPR) had negative free cash flow of $10.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Monopar Therapeutics Inc. (MNPR) 10-Year Financial Performance & Capital Metrics

MNPR • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$16M -83.0%
Net Income -$16M -85.5%
EPS (Diluted) -1.36 -134.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -51.42% +52.0%
ROIC -321.43% +94.3%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 20.9% through buybacks

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Expensive at 14.4x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-200.27%

EPS CAGR

10Y-

5Y-

3Y-

TTM-350%

ROCE

10Y Avg-75.7%

5Y Avg-67.43%

3Y Avg-79.5%

Latest-53.32%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	688.56K	1.19M	16.6M	3.4M	4.32M	6.51M	9.13M	10.54M	8.83M	16.16M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	587.08K	912.47K	1.17M	1.63M	2.36M	2.44M	2.63M	2.95M	3.23M	3.16M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	101.49K	280.36K	935.32K	1.77M	1.97M	4.07M	6.49M	7.59M	5.6M	13.01M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	14.5M	0	0	0	0	0	0	0
Operating Income+	-689K	-1.19M	-16.6M	-3.4M	-4.32M	-6.51M	-9.13M	-10.54M	-8.83M	-16.16M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.73%	-12.92%	0.8%	-0.27%	-0.51%	-0.4%	-0.15%	0.16%	-0.83%
EBITDA+	-438	0	-14.5M	-72K	-4.22M	0	-9.13M	-10.54M	-8.83M	-16.16M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	1%	-	1%	-57.68%	1%	-	-0.15%	0.16%	-0.83%
D&A (Non-Cash Add-back)	688.56K	1.19M	2.1M	3.33M	0	6.51M	0	0	0	0
EBIT	-687K	-1.18M	-16.55M	-3.33M	-4.22M	-6.51M	-9.13M	-10.54M	-8.83M	-16.16M
Net Interest Income+	0	0	0	0	98.89K	81.9K	24.02K	21.24K	429.04K	404.02K
Interest Income	1.25K	7.23K	48.26K	103.22K	98.89K	81.9K	24.02K	21.24K	429.04K	404.02K
Interest Expense	0	7.23K	48.26K	103.22K	0	0	0	0	0	0
Other Income/Expense	1.25K	7.23K	48.26K	31.15K	98.89K	204.3K	24.02K	21.24K	429.04K	575.3K
Pretax Income+	-687K	-1.18M	-16.55M	-3.3M	-4.22M	-6.3M	-9.1M	-10.52M	-8.4M	-15.59M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	800	0	-71.61K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.98%	1%	1%	1%	1%	1%	1%
Net Income+	-687K	-1.19M	-16.55M	-3.23M	-4.22M	-6.3M	-9.1M	-10.52M	-8.4M	-15.59M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.73%	-12.96%	0.81%	-0.31%	-0.49%	-0.44%	-0.16%	0.2%	-0.86%
Net Income (Continuing)	-687K	-1.19M	-16.55M	-3.23M	-4.22M	-6.3M	-9.1M	-10.52M	-8.4M	-15.59M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.08	-0.12	-1.59	-0.31	-0.40	-0.58	-0.73	-0.83	-0.58	-1.36
EPS Growth %	-	-0.43%	-12.25%	0.81%	-0.29%	-0.45%	-0.26%	-0.14%	0.3%	-1.34%
EPS (Basic)	-0.08	-0.12	-1.59	-0.31	-0.40	-0.58	-0.73	-0.83	-0.58	-1.36
Diluted Shares Outstanding	8.16M	9.86M	10.42M	10.42M	10.59M	10.96M	12.47M	12.72M	14.51M	11.48M
Basic Shares Outstanding	8.16M	9.85M	10.42M	10.42M	10.59M	10.96M	12.47M	12.72M	14.51M	11.44M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.03M	2.1M	9.13M	7.32M	13.23M	16.8M	20.52M	13.17M	7.33M	60.29M
Cash & Short-Term Investments	2.01M	2.07M	8.98M	6.89M	13.21M	16.74M	20.3M	13.12M	7.27M	60.21M
Cash Only	2.01M	2.07M	8.98M	6.89M	13.21M	16.74M	20.3M	8.19M	7.27M	45.82M
Short-Term Investments	0	0	0	0	0	0	0	4.93M	0	14.4M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	15.71K	62.69K	217.75K	45.98K	66.43K	78.87K
Total Non-Current Assets+	800K	800.39K	800.03K	410.67K	122.38K	68.86K	0	61.23K	12.65K	0
Property, Plant & Equipment	0	0	0	0	0	0	0	61.23K	12.65K	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	730.65M	0	0	0	0	0	0	0
Long-Term Investments	800K	800.39K	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	-729.85M	410.67K	122.38K	68.86K	0	0	0	0
Total Assets+	2.83M	2.9M	9.93M	7.32M	13.35M	16.87M	20.52M	13.23M	7.35M	60.29M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	0.02%	2.43%	-0.26%	0.82%	0.26%	0.22%	-0.36%	-0.44%	7.21%
Total Current Liabilities+	73.84K	64.51K	311.87K	399.55K	724.16K	1.18M	1.58M	3.13M	1.76M	5.25M
Accounts Payable	73.84K	64.51K	311.87K	399.55K	724.16K	1.18M	1.58M	3.13M	1.76M	2.25M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	0	0	0
Current Ratio	27.46x	32.48x	29.28x	18.32x	18.27x	14.28x	12.98x	4.21x	4.17x	11.47x
Quick Ratio	27.46x	32.48x	29.28x	18.32x	18.27x	14.28x	12.98x	4.21x	4.17x	11.47x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	0	8.41K	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	8.41K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	73.84K	64.51K	311.87K	399.55K	724.16K	1.18M	1.58M	3.14M	1.76M	5.25M
Total Debt+	0	0	0	0	0	0	0	8.41K	0	0
Net Debt	-2.01M	-2.07M	-8.98M	-6.89M	-13.21M	-16.74M	-20.3M	-8.18M	-7.27M	-45.82M
Debt / Equity	-	-	-	-	-	-	-	0.00x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-164.94x	-344.07x	-32.97x	-	-	-	-	-	-
Total Equity+	2.75M	2.83M	9.62M	6.92M	12.63M	15.69M	18.94M	10.09M	5.59M	55.04M
Equity Growth %	-	0.03%	2.4%	-0.28%	0.83%	0.24%	0.21%	-0.47%	-0.45%	8.85%
Book Value per Share	0.34	0.29	0.92	0.66	1.19	1.43	1.52	0.79	0.39	4.79
Total Shareholders' Equity	2.75M	2.83M	9.62M	6.92M	12.63M	15.69M	18.94M	10.09M	5.59M	55.04M
Common Stock	0	0	9.29K	9.29K	10.59K	11.45K	12.6K	12.95K	14.9K	6.1K
Retained Earnings	-687.31K	-1.87M	-18.43M	-21.66M	-25.88M	-32.19M	-41.29M	-51.8M	-60.21M	-75.79M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-2.4K	-10.97K	-7.87K	-3.16K	8.94K	-14.13K	35.99K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-636.33K	-1.19M	-2.63M	-2.89M	-3.02M	-4.66M	-7.32M	-7.23M	-7.86M	-6.4M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.88%	-1.2%	-0.1%	-0.05%	-0.54%	-0.57%	0.01%	-0.09%	0.19%
Net Income	-687.31K	-1.19M	-16.55M	-3.23M	-4.22M	-6.3M	-9.1M	-10.52M	-8.4M	-15.59M
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	0	0	305.2K	529.33K	1.01M	1.32M	1.47M	1.64M	1.9M	1.14M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-73.84K	9.33K	13.5M	441.65K	0	-122.4K	0	0	0	4.55M
Working Capital Changes	50.98K	-9.04K	120.58K	-188.16K	196.02K	443.81K	317.77K	1.65M	-1.35M	3.49M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	73.84K	-9.33K	247.36K	87.68K	243.53K	447.6K	403.97K	1.48M	-1.33M	506.79K
Cash from Investing+	0	0	0	0	0	0	0	-4.92M	4.93M	-14.34M
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	3.44M	1.26M	9.54M	-206.27K	9.35M	8.18M	10.88M	32.87K	2.03M	59.29M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	3.44M	0	4.83M	-206.27K	-874.81K	-115.57K	-45.77K	-76.46K	-46.97K	-104.14K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-636.33K	-1.19M	-2.63M	-2.89M	-3.02M	-4.66M	-7.32M	-7.23M	-7.86M	-6.4M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.88%	-1.2%	-0.1%	-0.05%	-0.54%	-0.57%	0.01%	-0.09%	0.19%
FCF per Share	-0.08	-0.12	-0.25	-0.28	-0.29	-0.43	-0.59	-0.57	-0.54	-0.56
FCF Conversion (FCF/Net Income)	0.93x	1.01x	0.16x	0.89x	0.71x	0.74x	0.80x	0.69x	0.94x	0.41x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-24.94%	-42.45%	-265.93%	-39.04%	-43.23%	-44.52%	-52.57%	-72.44%	-107.19%	-51.42%
Return on Invested Capital (ROIC)	-	-118.69%	-1784.05%	-769.75%	-	-	-	-2878.57%	-5671.91%	-321.43%
Debt / Equity	-	-	-	-	-	-	-	0.00x	-	-
Interest Coverage	-	-164.94x	-344.07x	-32.97x	-	-	-	-	-	-
FCF Conversion	0.93x	1.01x	0.16x	0.89x	0.71x	0.74x	0.80x	0.69x	0.94x	0.41x

Frequently Asked Questions

Growth & Financials

Monopar Therapeutics Inc. (MNPR) grew revenue by 0.0% over the past year. Growth has been modest.

Monopar Therapeutics Inc. (MNPR) reported a net loss of $19.4M for fiscal year 2024.

Dividend & Returns

Monopar Therapeutics Inc. (MNPR) has a return on equity (ROE) of -51.4%. Negative ROE indicates the company is unprofitable.

Monopar Therapeutics Inc. (MNPR) had negative free cash flow of $10.8M in fiscal year 2024, likely due to heavy capital investments.